Regeneron Pharmaceuticals, Inc. (REGN)
|Net Income (ttm)||7.00B|
|Day's Range||633.19 - 655.83|
|52-Week Range||441.00 - 686.62|
|Price Target||714.25 (+9.2%)|
|Earnings Date||Nov 4, 2021|
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent i... [Read more...]
Financial PerformanceFinancial Statements
According to 24 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is 714.25, which is an increase of 9.21% from the latest price.
New England Journal of Medicine publishes positive Phase 3 Dupixent® (dupilumab) results in children with moderate-to...
New England Journal of Medicine p ublishes p ositive Phase 3 Dupixent ® (dupilumab) results in children with moderate-to-severe asthma
New England Journal of Medicine Publishes Positive Phase 3 Dupixent® (dupilumab) Results in Children with Moderate-to...
TARRYTOWN, N.Y. and PARIS, Dec. 8, 2021 /PRNewswire/ -- Dupixent significantly reduced severe asthma attacks and improved lung function and asthma control in children aged 6 to 11 years with uncontroll...
Should investors be watching these biotech stocks with all the current focus on the Omicron Covid variant?
The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up ...
TARRYTOWN, N.Y., Dec. 3, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is scheduled to participate in a virtual fireside chat at the H.C.
Regeneron has made billions from its Covid-19 drug, and it has new drugs like Dupixent that could make many billions more. The post Regeneron: Surfing on Covid, With More Under the Surface appeared firs...
People should get vaccinated and boosted, Dr. Fauci says
Dr. Anthony Fauci, National Institute of Allergy and Infectious Diseases, speaks from the White House on the omicron variant, which was discovered in a patient in California.
Which companies see growth opportunities during rising Covid concerns
Michael Yee, Jefferies biotech analyst and managing director, joins 'Power Lunch' to discuss how company stocks are reacting to rising omicron concerns and which are the best to play with Covid concerns.
H.C. Wainwright recommends using the selloff today for Regeneron Pharmaceuticals Inc (NASDAQ:REGN) as a buying opportunity. The analyst keeps a Buy rating on Regeneron with an $844 price target.
Regeneron -- which markets REGEN-COV, the most widely used monoclonal antibody therapy to treat COVID-19 in the US -- cautioned that further studies are needed to determine whether the Omicron variant c...
Regeneron Pharmaceuticals' Covid-19 antibody cocktail, and similar drugs, could be less effective against the omicron coronavirus variant, the company said.
Regeneron CEO: We'll likely have to constantly adapt our antibody cocktail
Dr. Leonard Schleifler, founder and CEO of Regeneron, joins "Squawk Box" to discuss the company's monoclonal antibody treatment and the omicron variant.
Regeneron reports antibody treatment is less effective against omicron variant
CNBC's Meg Tirrell reports on the latest headlines from drugmakers and vaccine makers on the omicron variant.
Regeneron: Antibody cocktail is less effective against omicron
The "Squawk Box" team discusses a report from Regeneron that its antibody treatment is less effective against the omicron variant.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has extended the research term of its collaboration with Decibel Therapeutics Inc (NASDAQ: DBTX) to discover and develop gene therapies for hearing loss. Th...
The therapy will likely face stiff competition from more convenient COVID-19 pills.
TARRYTOWN, N.Y., Nov. 16, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Evercore ISI 4th Annual HealthCONx Conference at 9:15 a.m.
Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.
TARRYTOWN, N.Y., Nov. 15, 2021 /PRNewswire/ -- DJSI World highlights the most sustainable companies around the world by industry Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been recognized as a g...
TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that its Board of Directors authorized a share repurchase program of up to $3 billion of the...
The European Commission (EC) has approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail, known as REGEN-COV in the U.S. and Ronapreve in the European Union (EU) and other cou...
Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.
TARRYTOWN, N.Y., Nov. 12, 2021 /PRNewswire/ -- EC marketing authorization follows approvals in Japan, Australia and the UK Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Europea...
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) REGEN-COV. The casirivimab a...